In the JAVELIN solid tumor study, Avelumab, a human immunoglobin G1 anti-PD-L1 antibody, showed anti-tumor activity in platinum-refractory or cisplatin-ineligible patients, with 40% objective response rate in PD-L1-positive tumor cells in >5% of patients and 9% in PD-L1-positive cells in <5% of patients [43]. The gene discussed is CD274; the disease is neoplasm.